| Trial ID: | L3549 |
| Source ID: | NCT00427401
|
| Associated Drug: |
Pf-00915275
|
| Title: |
A Study To Evaluate PF-00915275 In Subjects With Type 2 Diabetes Mellitus For 4-Weeks
|
| Acronym: |
|
| Status: |
TERMINATED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Diabetes Mellitus, Type 2
|
| Interventions: |
DRUG: PF-00915275
|
| Outcome Measures: |
Primary: The primary end point is glucose lowering (24 hour mean glucose concentration). | Secondary: Fasting blood glucose
|
| Sponsor/Collaborators: |
Sponsor: Pfizer
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE2
|
| Enrollment: |
40
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE|Primary Purpose: TREATMENT
|
| Start Date: |
2007-02
|
| Completion Date: |
2007-06
|
| Results First Posted: |
|
| Last Update Posted: |
2008-09-29
|
| Locations: |
Pfizer Investigational Site, Bruxelles, 1070, Belgium
|
| URL: |
https://clinicaltrials.gov/show/NCT00427401
|
